• November 11, 2011 - S-Nitrosoglutathione Reductase Inhibitors for the Prevention and Treatment of Experimental Colitis
  • August 28, 2011 - Structure – Activity Relationships of Pyrrole Based S-Nitrosoglutathione Reductase Inhibitors – Carboxamide Modification
  • July 14, 2011 - Heterozygous Deletion of S-Nitrosoglutathione Reductase in Mice Does Not Increase Nitrosative Inactivation of O6-Alkylguanine-DNA Alkyltransferase or Diethylnitrosamine-induced Hepatocarcinogenesis
  • May 3, 2011 - Oral S-Nitrosoglutathione Reductase Inhibitors Attenuate Pulmonary Inflammation and Decrease Airspace Enlargement in Experimental Models of COPD
  • March 27, 2011 - Discovery of S-nitrosoglutathione reductase inhibitors as potential agents to treat asthma, COPD and IBD
More posters

March 13, 2013

N30 Announces First Patient Treated in Clinical Trial of N6022 in Cystic Fibrosis

Boulder, Colo., March 13, 2013–N30 Pharmaceuticals, Inc. (“N30 Pharma”) a leader in the development of therapeutics that target S-nitrosoglutathione reductase (GSNOR), announced today that it has administered the first dose in its Phase 1b/2a clinical trial of N6022 in patients with cystic fibrosis (CF).

The study is a multicenter, double-blind, randomized, placebo-controlled evaluation of ascending doses of N6022 in patients who have two copies of the F508del-CFTR mutation, the most common and serious form of CF.

The clinical study announced today is being conducted in collaboration with the Cystic Fibrosis Foundation’s Therapeutics Development Network (TDN), and the lead principal investigator for the study is Scott Donaldson, M.D., at The University of North Carolina, Chapel Hill. More…PDF (134Kb)

Comments are closed.